+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations